Ventyx Biosciences Faces Strategic Crossroads After Discontinuation of VTX958

Evercore ISI Group's Joshua Schimmer downgraded their rating on Ventyx Biosciences (NASDAQ: VTYX) from Buy to Hold on 2023/11/10. The analyst also lowered their price target by 88.4% from $43 to $5.

According to the analyst, the downgrade came after Ventyx Biosciences announced the discontinuation of Phase 2 data for their drug VTX958 in psoriasis and psoriatic arthritis. The company made this announcement on November 6th, 2023. As a result of this news, all forecasted revenue from the asset was removed, leading to the downgrade. Schimmer noted that the stock will remain downgraded until there is further clarity on the company's path forward.

In light of VTX958 not advancing, the analyst outlined three potential strategic options for the company. The first option is to outlicense both NLRP3 assets and commit to a Phase 3 UC trial for '002. The second option is to outlicense '002 and focus solely on NLRP3 development. The third option is to outlicense or partner '002, seek partnerships for "large lift indications" for NLRP3, and concentrate on select NLRP3 indications.

It is worth mentioning that none of the top-rated analysts currently rate Ventyx Biosciences as a Strong Buy or Buy. All analysts view it as a Hold, with no recommendations to sell the stock.

Since VTYX's latest quarterly report on November 6th, 2023, the stock price has experienced a significant decline of 83.3%. Year-over-year, the stock is down by a staggering 91%. During this period, VTYX has been trailing behind the S&P 500, which itself has experienced a decline of 13.8%.

Joshua Schimmer, the Evercore ISI Group analyst, is ranked in the top 14% out of 4,397 Wall Street analysts by WallStreetZen. He has an impressive average return of 7.5% and a win rate of 47.7%. Schimmer specializes in the Healthcare and Industrials sectors.

Ventyx Biosciences Incorporated is a biopharmaceutical company primarily focused on the development of small molecule products for inflammatory diseases and autoimmune disorders. The company's key product candidates include VTX958, a tyrosine kinase type 2 inhibitor currently in Phase I clinical trials for immune-mediated diseases, and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for systemic inflammatory diseases. Furthermore, the company is also working on CNS-penetrant NLRP3 inhibitors for the treatment of neurodegenerative disorders such as Alzheimer's disease. Ventyx Biosciences was established in 2018 and has its headquarters in Encinitas, CA.

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen and Don Francis do not hold any positions in the companies mentioned in this article. The information and statistics provided herein are presented for general informational purposes only and may not be accurate, complete, or up-to-date. It should not be interpreted as a recommendation to buy or sell any stocks and should not be solely relied upon for making investment decisions. It does not take into account your financial situation or risk profile. All investors should conduct their own investment due diligence before buying a stock. WallStreetZen expressly disclaims any liability for the accuracy, reliability, or completeness of the analysts' information, price targets, ratings, or opinions.